Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|January 17, 2014

Stevens Institute of Technology Opens Biotechnology and Drug–Discovery Laboratory

The Stevens Institute of Technology will open a new biotechnology laboratory in January 2014.

The Center for Healthcare Innovation at Stevens Institute of Technology will open its Biotechnology and Drug-Discovery Laboratory in January 2014 as a new biotechnology and drug discovery enterprise that will partner with other Stevens faculty, students, and external academic and industry collaborators. Established in part with a donation of equipment and supplies from Hoffmann-La Roche and support from the New Jersey Department of Labor, seven former Roche personnel recently joined Stevens as faculty and researchers in this new initiative. Laboratory staff also includes three new professors with R&D experience in pharmaceutical and biotechnology corporate laboratories. The laboratory will serve as a center for research in the areas of preclinical gene cloning and purification of therapeutic proteins, assay development, and robotic drug screening.


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.